ELAHERE (mirvetuximab soravtansine-gynx) injection

ELAHERE is a prescription medicine used to treat ovarian cancer. FDA approved mirvetuximab soravtansine-gynx (brand name ELAHERE) is not (yet) registered or available in India but on request Indian patient can buy ELAHERE at the lowest price.

Elahere-Mirvetuximab-soravtansine-gynxa
ELAHERE (mirvetuximab soravtansine-gynx) injection

Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!

For Indian Patient Enquiry under NPP.

For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.

ELAHERE (mirvetuximab soravtansine-gynx) injection

Mirvetuximab soravtansine-gynx injection is used to treat certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer

ELAHERE is a prescription medicine used to treat adults with folate receptor-alpha positive ovarian cancer, fallopian tube
cancer, or primary peritoneal cancer who:
• have not responded to or are no longer responding to treatment with platinum-based chemotherapy and
• have received 1 to 3 prior types of chemotherapy.
Your healthcare provider will perform a test to make sure that ELAHERE is right for you.
It is not known if ELAHERE is safe and effective in children.

Mirvetuximab soravtansine-gynx injection is used to treat certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) cancer in people who have completely responded or partially responded to their first or later chemotherapy treatments. Mirvetuximab soravtansine-gynx is in a class of medications called folate receptor alpha-directed antibody and microtubule inhibitor conjugates. It works by killing cancer cells.

ELAHERE (mirvetuximab soravtansine-gynx) injection, for intravenous use Initial U.S. Approval: 2022
—————-
Current Indication: Treat adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary
peritoneal cancer
—————-
Marketed By: ImmunoGen
—————-
Approval Date: : 2022
—————-
Active ingredient: mirvetuximab soravtansine-gynx
—————-
Inactive ingredients: glacial acetic acid, polysorbate 20, sodium acetate, sucrose, Water for Injection.
—————-

Injection: 100 mg/20 mL (5 mg/mL) in a single-dose vial

For more highlights of prescribing information regarding Indications and usage, dosage and administration, dosage forms and strengths, patient counseling information and medication guide. Click Here

Alleviare Life Sciences

About Us

Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.

Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.

Alleviare India, a certified pharmaceutical facilitator / supplier / importer of specialty medicines or drugs based in India.